The Value of Gene Therapies

Roshawn Blunt, managing director of 1798, a Fingerpaint company, was featured in the Med Ad News article, “Value of Gene Therapies for Rare (and Not So Rare) Diseases.”

The article discusses how to develop affordable ways to treat rare diseases, making therapies more accessible to those who need them the most.

“It’s important to dive in even deeper and ask what is the definition of access. To say that payers are covering it doesn’t mean that it’s perfectly even coverage or that it’s coverage as to what the FDA label says,” Blunt told the media outlet.

Blunt notes the importance of marketing comprehensive and the considerate value rooted in early conversations with payers.